Final month marked continued progress as digital well being strikes into its subsequent part — from AI increasing into drug discovery and core infrastructure to new federal pathways accelerating gadget entry and home-based care. Collectively, these shifts sign a turning level towards real-world scale.
Right here’s a better take a look at the important thing developments driving that momentum.
Expertise, Information, and Insights
CMS Launches First Wave of HealthTech Ecosystem Instruments, Quick‑Monitoring a Absolutely Digital, Affected person‑Centered Well being System
CMS launched the primary wave of its HealthTech Ecosystem initiative, rolling out new interoperable instruments, a Medicare app library, and patient-facing functions designed to streamline how people entry and handle their well being information. The trouble brings collectively a whole lot of organizations aligned round shared requirements for id, safety, and information alternate.
Learn the complete CMS press launch right here >>
Self-Powering Sensible Materials Sign Subsequent Part of Wearables
Researchers are growing sensor-embedded materials that may observe well being metrics like coronary heart fee, respiration, and temperature whereas producing energy from physique warmth and motion. The know-how might be built-in into on a regular basis clothes, yoga mats, wristbands, and even bedsheets, enabling steady monitoring with out the necessity for charging or standalone units.
This factors to a broader shift from device-based wearables to ambient well being monitoring, the place information assortment turns into passive, always-on, and embedded into every day life.
Learn the complete TechRadar article right here >>
OpenAI Companions with Novo Nordisk to Speed up AI-Pushed Drug Discovery
Novo Nordisk introduced a strategic partnership with OpenAI to combine superior AI throughout its drug growth pipeline, utilizing large-scale information evaluation to determine new drug candidates and speed up time from analysis to affected person supply. The collaboration may also lengthen into manufacturing, provide chain, and industrial operations, signaling a broader shift towards end-to-end AI integration in pharma.
Learn the complete MobiHealthNews article right here >>
Coverage and Regulatory
FDA to Overview Peptides for Potential Compounding Entry in July Advisory Assembly
The FDA introduced it’ll convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23–24 to judge whether or not seven peptides needs to be added to the 503A bulk drug substances record. A key step that might permit licensed 503A pharmacies to compound them with a sound, patient-specific prescription. The substances below evaluate embody peptides tied to situations like weight problems, wound therapeutic, irritation, and sleep problems.
Learn the complete FDA announcement right here >>
FDA Launches READI-House Innovation Problem to Advance House-Primarily based Care
The FDA launched the READI-House Innovation Problem, a brand new initiative aimed toward accelerating growth of medical units designed to be used within the dwelling to scale back hospital readmissions. This system invitations innovators to submit applied sciences that help sufferers and caregivers following acute care episodes, with a give attention to bettering outcomes and stopping avoidable returns to the hospital.
Learn the complete FDA announcement right here >>
CMS and FDA announce RAPID Pathway to Speed up Medical System Protection
CMS and the FDA launched the RAPID (Regulatory Alignment for Predictable and Quick System) protection pathway, designed to hurry up Medicare entry to breakthrough medical units by aligning regulatory approval and reimbursement processes. This system permits earlier collaboration between regulators and producers in order that medical proof generated for FDA evaluate may also help Medicare protection choices.
Learn the complete FDA announcement right here >>
DOJ Strikes to Reclassify Medical Marijuana, Increasing Entry and Analysis Pathways
The Division of Justice introduced it’ll place FDA-approved and state-regulated medical marijuana merchandise into Schedule III, a transfer that acknowledges their medical use whereas sustaining federal oversight. The choice expands entry to accredited therapies, helps state applications, and permits broader analysis into security and efficacy — alongside an expedited course of to judge full federal rescheduling.
Learn the complete DOJ announcement right here >>
Learn extra at Openloop!
